Zobrazeno 1 - 10
of 58
pro vyhledávání: '"Zoheir Bshouty"'
Publikováno v:
Pulmonary Medicine, Vol 2018 (2018)
Background. Specific therapy for patients with PAH is associated with good outcomes. Little is known about the effect of this treatment in patients with Cpc-PH (PAPm ≥ 25 mmHg, PAWP > 15 mmHg, DPG ≥ 7 mmHg, and/or PVR > 3 WU). This study evaluate
Externí odkaz:
https://doaj.org/article/98d31dbe9d3f422a97c60a11918b6358
Publikováno v:
Canadian Respiratory Journal, Vol 20, Iss 2, Pp 111-115 (2013)
BACKGROUND: The most effective approaches to escalating advanced therapies in pulmonary arterial hypertension (PAH) are controversial.
Externí odkaz:
https://doaj.org/article/f8e17e75c6974ae0b62defef362ec919
Autor:
Zoheir Bshouty
Publikováno v:
Canadian Respiratory Journal, Vol 19, Iss 3, Pp 209-215 (2012)
A previously validated computer model of the normal pulmonary circulation is adapted to simulate pulmonary arterial hypertension (PAH) in humans. Model predictions are used to explore the suitability of currently accepted criteria for diagnosing PAH
Externí odkaz:
https://doaj.org/article/2ef81093bc8242a0963b9f274347837e
Publikováno v:
Canadian Respiratory Journal, Vol 17, Iss 6, Pp 282-286 (2010)
BACKGROUND: Pulmonary hypertension (PH) in patients with connective tissue disease (CTD) can occur in isolation or concomitantly with interstitial lung disease (ILD). Targeted therapies for PH can mitigate clinical deterioration in CTD patients with
Externí odkaz:
https://doaj.org/article/c9bbf6018daa426ba5aaec9b4c5a2c1b
Publikováno v:
Canadian Respiratory Journal, Vol 16, Iss 6, Pp 189-193 (2009)
BACKGROUND: Pulmonary function tests (PFTs) are commonly interpreted as a fraction of predicted normal values, with an abnormal test often defined as less than 80% or greater than 120% of the predicted value. However, recommendations of the American
Externí odkaz:
https://doaj.org/article/c63117dff1be444380bcbf1cb6c302b2
Publikováno v:
Canadian Respiratory Journal, Vol 15, Iss 8, Pp 427-430 (2008)
BACKGROUND: Pulmonary arterial hypertension (PAH) remains a progressive disease despite improvement when using one of three medication classes: prostanoids, endothelin receptor antagonists or phosphodiesterase-5 inhibitors. Combination therapy has be
Externí odkaz:
https://doaj.org/article/5c0cb8f5b08c47ca9f6faa5bda7ab543
Publikováno v:
Canadian Respiratory Journal, Vol 15, Iss 4, Pp 199-202 (2008)
BACKGROUND: Bronchiolitis obliterans syndrome (BOS), the main cause of late mortality following lung transplantation, is defined as an irreversible decline in forced expiratory volume in 1 s (FEV1).Previous studies using azithromycin for BOS in lung
Externí odkaz:
https://doaj.org/article/b6a047fe691b4c0eb8775400a28423f8
Autor:
Kimberley Mulchey, Zoheir Bshouty
Publikováno v:
Canadian Respiratory Journal, Vol 16, Iss 5, Pp e54-e56 (2009)
Hepatocellular enzyme elevation is a known side effect of both bosentan and atorvastatin. However, a rise in liver enzyme level not characteristic of either agent individually may represent a reaction to their combination or an atypical reaction to b
Externí odkaz:
https://doaj.org/article/4d7bb7e140e34d6ab0992a42e4a29ce9
Autor:
Naseer Ahmed, Tedros Bezabeh, Omkar B. Ijare, Renelle Myers, Reem Alomran, Michel Aliani, Zoann Nugent, Shantanu Banerji, Julian Kim, Gefei Qing, Zoheir Bshouty
Publikováno v:
Magnetic Resonance Insights, Vol 2016, Iss 9, Pp 29-35 (2016)
Magnetic Resonance Insights, Vol 9 (2016)
Magnetic Resonance Insights, Vol 9 (2016)
Objectives Lung cancer is one of the most lethal cancers. Currently, there are no biomarkers for early detection, monitoring treatment response, and detecting recurrent lung cancer. We undertook this study to determine if 1 H magnetic resonance spect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::d06191cc416d0fd46ffaf5c4c377da83
http://www.la-press.com/metabolic-signatures-of-lung-cancer-in-sputum-and-exhaled-breath-conde-article-a6031
http://www.la-press.com/metabolic-signatures-of-lung-cancer-in-sputum-and-exhaled-breath-conde-article-a6031
Autor:
András Temesvári, Sigita Aidietienė, Vladimir M. Shipulin, Jae Seung Lee, Pavel Jansa, Nuofu Zhang, Dominik Richard, Nguyen Vinh Pham, Carlos Jerjes Sanchez, Lan Hieu Nguyen, Keertan Dheda, Christian M. Kähler, Olga Barbarash, Piotr Podolec, Tomas Rene Pulido Zamudio, Michael M. Madani, Hyung Kwan Kim, Suree Sompradeekul, Grégoire Prévot, Silvia Ulrich, Luke Howard, Nattapong Jaimchariyatam, Olga Moiseeva, Gulfer Okumus, Zoheir Bshouty, Arintaya Phrommintikul, Friedrich Grimminger, David P. Jenkins, Heinrike Wilkens, Robin Condliffe, Irene Lang, John-David Aubert, Rudolf Speich, Tatiana Mularek-Kubzdela, Nicolas Martin, Hélène Bouvaist, Stephan Rosenkranz, Jun Bean Park, Peter F. Fedullo, Luke S. Howard, Olivier Sanchez, Gérald Simonneau, Ryszard Grzywna, Alexander Chernyavskiy, Zhi-Cheng Jing, Joanna Pepke-Zaba, Anton Vonk Noordegraaf, Andrea Maria D'Armini, Pablo Sepulveda Varela, Gang-Cheng Zhang, Nick H. Kim, Eckhard Mayer, Jerzy Lewczuk, Yuhong Mi, Zeynep Pinar Onen, Ekkehard Grünig, Xian-Yang Zhu, Marion Delcroix, John McConnell, Yuanhua Yang, Jin-Ming Liu, Lyubomyr Solovey, Kelly Papadakis, Xavier Jaïs, Istvan Edes, Tamila Vitalievna Martynyuk, Matthias Held, Kristóf Karlócai, Jarosław Kasprzak, Skaidrius Miliauskas, Hossein Ardeschir Ghofrani, Kim M. Kerr, Volodymyr Gavrysyuk
Publikováno v:
Ghofrani, H A, Simonneau, G, D'Armini, A M, Fedullo, P, Howard, L S, Jaïs, X, Jenkins, D P, Jing, Z C, Madani, M M, Martin, N, Mayer, E, Papadakis, K, Richard, D, Kim, N H, Noordegraaf, A V & MERIT study investigators 2017, ' Macitentan for the treatment of inoperable chronic thromboembolic pulmonary hypertension (MERIT-1) : results from the multicentre, phase 2, randomised, double-blind, placebo-controlled study ', The Lancet Respiratory Medicine, vol. 5, no. 10, pp. 785-794 . https://doi.org/10.1016/S2213-2600(17)30305-3
The Lancet Respiratory Medicine, 5(10), 785-794. Elsevier Limited
The Lancet Respiratory Medicine, 5(10), 785-794. Elsevier Limited
Summary Background Macitentan is beneficial for long-term treatment of pulmonary arterial hypertension. The microvasculopathy of chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension are similar. Methods The phase
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36794781d5eccbc59c72cb8cc5a212e5
https://research.vumc.nl/en/publications/4d05f687-13a9-445c-ba49-7129684838f4
https://research.vumc.nl/en/publications/4d05f687-13a9-445c-ba49-7129684838f4
